Meta-Analysis of Effectiveness and Safety of D2 Plus Para-Aortic Lymphadenectomy for Resectable Gastric Cancer

Journal of the American College of Surgeons

Volumn 210, Issue 1, 2010, Pages 100-105

  Chen, Xin Zu ^a   Hu, Jian Kun ^a   Zhou, Zong Guang ^a   Rui, Yuan Yi ^a   Yang, Kun ^a   Wang, Li ^a   Zhang, Bo ^a   Chen, Zhi Xin ^a   Chen, Jia Ping ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ABDOMINAL ABSCESS; ANASTOMOSIS LEAKAGE; CANCER MORTALITY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; HEART DISEASE; HUMAN; ILEUS; LUNG COMPLICATION; LYMPHADENECTOMY; META ANALYSIS; MORBIDITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS FISTULA; PARAAORTIC LYMPH NODE; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; REVIEW; STOMACH CANCER; STOMACH OBSTRUCTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; WOUND INFECTION;

HOSPITAL MORTALITY; HUMANS; INCIDENCE; LYMPH NODE EXCISION; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 72049106431     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jamcollsurg.2009.09.033     Document Type: Review

References (37)

1. Kamangar F., Dores G.M., and Anderson W.F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24 (2006) 2137-2150
2. Yao J.C., Mansfield P.F., Pisters P.W., et al. Combined-modality therapy for gastric cancer. Semin Surg Oncol 21 (2003) 223-227
3. Jeung H.C., Rha S.Y., Noh S.H., et al. Adjuvant 5-fluorouracil plus doxorubicin in D2-3 resected gastric carcinoma: 15-year experience at a single institute. Cancer 91 (2001) 2016-2025
4. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: gastric cancer (2008). http://www.nccn.org/professionals/physician_gls/PDF/gastric.pdf Accessed October 27, 2008
5. Chen X.Z., Jiang K., Hu J.K., et al. Cost-effectiveness analysis of chemotherapy for advanced gastric cancer in China. World J Gastroenterol 14 (2008) 2715-2722
6. Hsu C.P., Wu C.C., Chen C.Y., et al. Clinical experience in radical lymphadenectomy for adenocarcinoma of the gastric cardia. J Thorac Cardiovasc Surg 114 (1997) 544-551
7. den Dulk M., Verheij M., Cats A., et al. The essentials of locoregional control in the treatment of gastric cancer. Scand J Surg 95 (2006) 236-242
8. Volpe C.M., Koo J., Miloro S.M., et al. The effect of extended lymphadenectomy on survival in patients with gastric adenocarcinoma. J Am Coll Surg 181 (1995) 56-64
9. Ramacciato G., Aurello P., D'Angelo F., et al. Does extended lymphadenectomy influence prognosis of gastric carcinoma after curative resection?. Hepatogastroenterology 47 (2000) 1470-1474
10. Danielson H., Kokkola A., Kiviluoto T., et al. Clinical outcome after D1 vs D2-3 gastrectomy for treatment of gastric cancer. Scand J Surg 96 (2007) 35-40
11. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma. 2nd English edition. Gastric Cancer 1 (1998) 10-24
12. Cuschieri A., Fayers P., Fielding J., et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet 347 (1996) 995-999
13. Cuschieri A., Weeden S., Fielding J., et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 79 (1999) 1522-1530
14. Kodera Y., Sasako M., Yamamoto S., et al. Identification of risk factors for the development of complications following extended and superextended lymphadenectomies for gastric cancer. Br J Surg 92 (2005) 1103-1109
15. Sakuramoto S., Sasako M., Yamaguchi T., et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357 (2007) 1810-1820
16. McCulloch P., Niita M.E., Kazi H., et al. Gastrectomy with extended lymphadenectomy for primary treatment of gastric cancer. Br J Surg 92 (2005) 5-13
17. Roukos D.H., Paraschou P., and Lorenz M. Distal gastric cancer and extensive surgery: a new evaluation method based on the study of the status of residual lymph nodes after limited surgery. Ann Surg Oncol 7 (2000) 719-726
18. Maeta M., Yamashiro H., Saito H., et al. A prospective pilot study of extended (D3) and superextended para-aortic lymphadenectomy (D4) in patients with T3 or T4 gastric cancer managed by total gastrectomy. Surgery 125 (1999) 325-331
19. Kunisaki C., Takahashi M., Fukushima T., et al. The influence of stage migration on the comparison of surgical outcomes between D2 gastrectomy and D3 gastrectomy (para-aortic lymph node dissection): a multi-institutional retrospective study. Am J Surg 196 (2008) 358-363
20. Sano T., Sasako M., Yamamoto S., et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy-Japan Clinical Oncology Group study 9501. J Clin Oncol 22 (2004) 2767-2773
21. Yonemura Y., Wu C.C., Fukushima N., et al. Metastasis in para-aortic lymph nodes in patients with advanced gastric cancer, treated with extended lymphadenectomy. Hepatogastroenterology 54 (2007) 634-638
22. Shimoyama S., Mafune K., and Kaminishi M. Safety of a paraaortic node dissection for selected advanced gastric cancer patients. Hepatogastroenterology 52 (2005) 1631-1635
23. Bostanci E.B., Kayaalp C., Ozogul Y., et al. Comparison of complications after D2 and D3 dissection for gastric cancer. Eur J Surg Oncol 30 (2004) 20-25
24. Kulig J., Popiela T., Kolodziejczyk P., et al. Standard D2 versus extended D2 (D2+) lymphadenectomy for gastric cancer: an interim safety analysis of a multicenter, randomized, clinical trial. Am J Surg 193 (2007) 10-15
25. Wu C.W., Hsiung C.A., Lo S.S., et al. Randomized clinical trial of morbidity after D1 and D3 surgery for gastric cancer. Br J Surg 91 (2004) 283-287
26. Sasako M., Sano T., Yamamoto S., et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 359 (2008) 453-462
27. Jadad A.R., Moore R.A., Carroll D., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 17 (1996) 1-12
28. In: Higgins J.P.T., and Green S. (Eds). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.1 [updated September 2008]. The Cochrane Collaboration (2008). http://www.cochrane-handbook.org Available at: www.cochrane-handbook.org. Accessed July 2, 2009
29. Yonemura Y., Wu C.C., Fukushima N., et al. Operative morbidity and mortality after D2 and D4 extended dissection for advanced gastric cancer: a prospective randomized trial conducted by Asian surgeons. Hepatogastroenterology 53 (2006) 389-394
30. Yonemura Y., Wu C.C., Fukushima N., et al. Randomized clinical trial of D2 and extended paraaortic lymphadenectomy in patients with gastric cancer. Int J Clin Oncol 13 (2008) 132-137
31. Takashima S., and Kosaka T. Results and controversial issues regarding a para-aortic lymph node dissection for advanced gastric cancer. Surg Today 35 (2005) 425-431
32. Isozaki H., Okajima K., Fujii K., et al. Effectiveness of paraaortic lymph node dissection for advanced gastric cancer. Hepatogastroenterology 46 (1999) 549-554
33. Kunisaki C., Shimada H., Yamaoka H., et al. Indications for paraaortic lymph node dissection in gastric cancer patients with paraaortic lymph node involvement. Hepatogastroenterology 47 (2000) 586-589
34. Nomura E., Sasako M., Yamamoto S., et al. Risk factors for para-aortic lymph node metastasis of gastric cancer from a randomized controlled trial of JCOG9501. Jpn J Clin Oncol 37 (2007) 429-433
35. Kosaka T., Usami K., Ueshige N., et al. Paraaortic lymph node dissection for gastric cancer in 244 consecutive cases. Hepatogastroenterology 53 (2006) 629-633
36. Yoshikawa T., Sasako M., Sano T., et al. Stage migration caused by D2 dissection with para-aortic lymphadenectomy for gastric cancer from the results of a prospective randomized controlled trial. Br J Surg 93 (2006) 1526-1529
37. Wu C.W., Hsiung C.A., Lo S.S., et al. Stage migration influences on stage-specific survival comparison between D1 and D3 gastric cancer surgeries. Eur J Surg Oncol 31 (2005) 153-157